Evidence map›Paper›PMID 36400098›Full record

SynthesisThe Lancet. Oncology2022

5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney).

Shankar Siva, Muhammad Ali, Rohann J M Correa, Alexander Muacevic, Lee Ponsky, Rodney J Ellis, Simon S Lo, Hiroshi Onishi, Anand Swaminath, Mark McLaughlin and 11 more

2 registry-linked trialsAbstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in The Lancet. Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 58 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 1 pooled it
18.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07285538 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

A Prospective Interventional Study of Stereotactic Body RadioTherapy (SBRT) With Continuous Tracking for Inoperable Patients With Primary and Secondary Renal Cancer (SBRTRC)

TypeinterventionalSponsorIRCCS San RaffaeleRan2026 to 2033Enrolled60ConditionsRenal Cancer, Renal Secondary Cancer, Stereotactic Body RadiotherapyArmsStereotactic body radiotherapy (SBRT)
NCT07299357 recruitingnot on this mapstarted 2026, after this paper: background citation

Prospective Observational Trial of Image-guided Ablative STereotactic bOdy Radiation Therapy for Primary kidNey Cancer: the STONE Trial

TypeobservationalSponsorIstituto Clinico HumanitasRan2026 to 2033Enrolled53ConditionsRenal CancerArmsStereotactic body radiotherapy (SBRT)
3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 1 synthesis or guideline pooled it, 126 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 14 institutions in 4 countries.

Shankar SivaDepartment of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia. Electronic address: shankar.siva@petermac.org.
Muhammad AliDepartment of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia.
Rohann J M CorreaDepartment of Radiation Oncology, London Regional Cancer Program, London, ON, Canada.
Alexander MuacevicEuropean Radiosurgery Center Munich, University of Munich Hospitals, Munich, Germany.
Lee PonskyDepartment of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Rodney J EllisGenesisCare USA, Fort Myers, FL, USA.
Simon S LoDepartment of Radiation Oncology, University of Washington School of Medicine, Seattle, WA, USA.
Hiroshi OnishiDepartment of Radiology, University of Yamanashi, Yamanashi, Japan.
Anand SwaminathDepartment of Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada.
Mark McLaughlinDepartment of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Scott C MorganDepartment of Radiology, Radiation Oncology and Medical Physics, The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.
Fabio L CuryDivision of Radiation Oncology, Department of Oncology, McGill University Health Centre, Montreal, QC, Canada.
Bin S TehDepartment of Radiation Oncology, Houston Methodist Hospital, Cancer Center and Research Institute, Houston, TX, USA.
Anand MahadevanDepartment of Radiation Oncology, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.
Irving D KaplanDepartment of Radiation Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
William ChuSunnybrook Health Sciences Centre, Toronto, ON, Canada; Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
William GrubbDepartment of Radiation Oncology, Augusta University, Augusta, GA, USA.
Raquibul HannanDepartment of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Michael StaehlerDepartment of Urology, University of Munich Hospitals, Munich, Germany.
Andrew WarnerDepartment of Radiation Oncology, London Regional Cancer Program, London, ON, Canada.
Alexander V LouieSunnybrook Health Sciences Centre, Toronto, ON, Canada; Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
Cancer Care Ontario · CASunnybrook Health Science Centre · CAThe University of Texas Southwestern Medical Center · USAugusta University · USBeth Israel Deaconess Medical Center · USMcGill University Health Centre · CAMcMaster University · CAMethodist Hospital · USOttawa Hospital · CAPeter MacCallum Cancer Centre · AUUniversity of Melbourne · AUUniversity of Washington · USUniversity of Yamanashi · JPUniversity School · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStereotactic ablative body radiotherapy (SABR) is a non-invasive treatment option for primary renal cell carcinoma, for which long-term data are awaited. The primary aim of this study was to report on long-term efficacy and safety of SABR for localised renal cell carcinoma.

methodsThis study was an individual patient data meta-analysis, for which patients undergoing SABR for primary renal cell carcinoma across 12 institutions in five countries (Australia, Canada, Germany, Japan, and the USA) were eligible. Eligible patients had at least 2 years of follow-up, were aged 18 years or older, had any performance status, and had no previous local therapy. Patients with metastatic renal cell carcinoma or upper-tract urothelial carcinoma were excluded. SABR was delivered as a single or multiple fractions of greater than 5 Gy. The primary endpoint was investigator-assessed local failure per the Response Evaluation Criteria in Solid Tumours version 1.1, and was evaluated using cumulative incidence functions.

findings190 patients received SABR between March 23, 2007, and Sept 20, 2018. Single-fraction SABR was delivered in 81 (43%) patients and multifraction SABR was delivered in 109 (57%) patients. Median follow-up was 5·0 years (IQR 3·4-6·8). 139 (73%) patients were men, and 51 (27%) were women. Median age was 73·6 years (IQR 66·2-82·0). Median tumour diameter was 4·0 cm (IQR 2·8-4·9). 96 (75%) of 128 patients with available operability details were deemed inoperable by the referring urologist. 56 (29%) of 190 patients had a solitary kidney. Median baseline estimated glomerular filtration rate (eGFR) was 60·0 mL/min per 1·73 m

interpretationSABR is effective and safe in the long term for patients with primary renal cell carcinoma. Single-fraction SABR might yield less local failure than multifraction, but further evidence from randomised trials is needed to elucidate optimal treatment schedules. These mature data lend further support for renal SABR as a treatment option for patients unwilling or unfit to undergo surgery.

fundingNone.

Indexed as

Carcinoma, Renal CellCarcinoma, Transitional CellKidney NeoplasmsRadiosurgeryUrinary Bladder NeoplasmsAgedFemaleHumansKidneyMale

Identifiers

PMID36400098
OpenAlexW4309412449

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.